Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.23.3
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Basic and diluted numerator:    
Net loss available to iBio, Inc. stockholders $ (5,074) $ (7,537)
Loss from discontinued operations (672) (10,593)
Net loss available to iBio, Inc. stockholders $ (5,746) $ (18,130)
Basic and diluted denominator:    
Weighted-average common shares outstanding - basic 23,969 8,842
Weighted-average common shares outstanding - diluted 23,969 8,842
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.21) $ (0.85)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.21) (0.85)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (0.03) (1.20)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (0.03) (1.20)
Per share amount basic (0.24) (2.05)
Per share amount diluted $ (0.24) $ (2.05)